{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:45:26Z","timestamp":1793915126510,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clinthera.2022.08.004","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T07:32:54Z","timestamp":1661931174000},"page":"1187-1202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Systemic Corticosteroid\u2013related Adverse Outcomes and Health Care Resource Utilization and Costs Among Patients with Chronic Rhinosinusitis with Nasal Polyposis"],"prefix":"10.1016","volume":"44","author":[{"given":"Greg E.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Zeiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung N.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Katial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Kreindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tkacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.08.004_bib0001","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/all.13042","article-title":"Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample","volume":"72","author":"Hirsch","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2500\/aap.2019.40.4182","article-title":"A cross-sectional, population-based survey of U.S. adults with symptoms of chronic rhinosinusitis","volume":"40","author":"Palmer","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0003","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaip.2018.10.014","article-title":"Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting","volume":"7","author":"Benjamin","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0004","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0006","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jaci.2013.02.002","article-title":"Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis","volume":"131","author":"Tan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0007","first-page":"57","article-title":"Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients","volume":"42","author":"Lund","year":"2004","journal-title":"Rhinology"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/archotol.132.2.179","article-title":"A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis","volume":"132","author":"Stj\u00e4rne","year":"2006","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0009","article-title":"Different types of intranasal steroids for chronic rhinosinusitis","volume":"4","author":"Chong","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1945892419851312","article-title":"Efficacy of short-term systemic corticosteroid therapy in chronic rhinosinusitis with nasal polyps: a meta-analysis of randomized controlled trials and systematic review","volume":"33","author":"Zhang","year":"2019","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0011","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/alr.21072","article-title":"Oral corticosteroids in the management of adult chronic rhinosinusitis with and without nasal polyps: an evidence-based review with recommendations","volume":"3","author":"Poetker","year":"2012","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMcp1800215","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"381","author":"Hopkins","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0013","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0014","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0015","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.jaip.2020.06.055","article-title":"Systemic corticosteroid-related complications and costs in adults with persistent asthma","volume":"8","author":"Zeiger","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0016","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/all.13556","article-title":"Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma","volume":"74","author":"Voorham","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0017","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13601-019-0303-6","article-title":"Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper","volume":"10","author":"Hox","year":"2020","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0019","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jaip.2016.12.023","article-title":"Burden of chronic oral corticosteroid use by adults with persistent asthma","volume":"5","author":"Zeiger","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0021","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0022","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","article-title":"Acute and chronic systemic corticosteroid-related complications in patients with severe asthma","volume":"136","author":"Lefebvre","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0023","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/03007995.2016.1233101","article-title":"Burden of systemic glucocorticoid-related complications in severe asthma","volume":"33","author":"Lefebvre","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.clinthera.2022.08.004_bib0024","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.anai.2020.08.162","article-title":"Health care resource use and costs for patients with chronic rhinosinusitis with nasal polyposis","volume":"125","author":"Davis","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0025","unstructured":"Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision. Clinical Modification (ICD-9-CM). Available at: https:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm. Accessed May 4, 2022."},{"key":"10.1016\/j.clinthera.2022.08.004_bib0026","unstructured":"Centers for Disease Control and Prevention. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Available at: https:\/\/www.cdc.gov\/nchs\/icd\/icd-10-cm.htm. Accessed May 4, 2022."},{"key":"10.1016\/j.clinthera.2022.08.004_bib0027","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0028","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/0091270003258651","article-title":"Dose equivalency of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics","volume":"43","author":"Mager","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0029","first-page":"833","article-title":"Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma","volume":"22","author":"Dalal","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"S29","key":"10.1016\/j.clinthera.2022.08.004_bib0030","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.clinthera.2022.08.004_bib0031","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:45Z","timestamp":1758963465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822002831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0149291822002831"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Corticosteroid\u2013related Adverse Outcomes and Health Care Resource Utilization and Costs Among Patients with Chronic Rhinosinusitis with Nasal Polyposis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AstraZeneca. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}